Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer.
The company was founded in 2017 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -0.36 Decreased by -2.86% | -0.35 Decreased by -4.08% |
| Mar 17, 25 | -0.34 Decreased by -6.25% | -0.34 Increased by +0.82% |
| Nov 6, 24 | -0.27 Decreased by -17.39% | -0.37 Increased by +27.03% |
| Aug 7, 24 | -0.24 Decreased by -4.35% | -0.34 Increased by +29.41% |
| May 8, 24 | -0.35 Decreased by -9.37% | -0.31 Decreased by -12.90% |
| Mar 18, 24 | -0.32 Increased by +3.03% | -0.28 Decreased by -14.29% |
| Nov 8, 23 | -0.23 Increased by +30.30% | -0.34 Increased by +32.35% |
| Aug 7, 23 | -0.23 Increased by +17.86% | -0.34 Increased by +32.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 5.39 M Decreased by -16.67% | -39.88 M Decreased by -5.17% | Decreased by -739.54% Decreased by -26.22% |
| Dec 31, 24 | 4.12 M Decreased by -24.19% | -37.67 M Decreased by -22.45% | Decreased by -914.99% Decreased by -61.53% |
| Sep 30, 24 | 11.61 M Increased by +8.15% | -29.17 M Decreased by -31.01% | Decreased by -251.29% Decreased by -21.13% |
| Jun 30, 24 | 19.88 M Increased by +36.15% | -25.55 M Decreased by -23.38% | Decreased by -128.56% Increased by +9.38% |
| Mar 31, 24 | 6.47 M Increased by +12.23% | -37.91 M Decreased by -47.35% | Decreased by -585.91% Decreased by -31.30% |
| Dec 31, 23 | 5.43 M Decreased by -15.29% | -30.76 M Decreased by -5.86% | Decreased by -566.43% Decreased by -24.96% |
| Sep 30, 23 | 10.73 M Increased by +55.09% | -22.26 M Increased by +20.99% | Decreased by -207.45% Increased by +49.05% |
| Jun 30, 23 | 14.60 M Increased by +152.95% | -20.71 M Increased by +16.69% | Decreased by -141.87% Increased by +67.06% |